- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- BIVV009 6.5 grams, BIVV009 7.5 grams
- Drug
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- Georgetown, District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemophilia A
- Interventions
- DDAVP Inhalant Product, Exercise Intervention
- Drug · Behavioral
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 13 Years to 21 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Akron, Ohio • Columbus, Ohio + 1 more
- Conditions
- Hemophilia A
- Interventions
- valoctocogene roxaparvovec
- Biological
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 12 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- turoctocog alfa pegol
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 5
- States / cities
- Iowa City, Iowa • Lexington, Kentucky • Baltimore, Maryland + 2 more
- Conditions
- Immune Thrombocytopenia
- Interventions
- Romiplostim
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 16
- States / cities
- Roseville, California • Atlanta, Georgia • Chicago, Illinois + 13 more
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Not listed
- Enrollment
- 726 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hemophilia A
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Day to 99 Years · Male only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Blood Coagulation Disorders
- Interventions
- ROTEM sigma
- Device
- Lead sponsor
- Tem Innovations GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Baltimore, Maryland • New York, New York
- Conditions
- Obesity
- Interventions
- Hybrid Argon Plasma Coagulation, Endoscopic Sleeve Gastroplasty
- Procedure
- Lead sponsor
- True You Weight Loss
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Cary, North Carolina
- Conditions
- Severe Hemophilia A
- Interventions
- Human-cl rhFVIII
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Embolism, Air
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hemophilia A, Congenital
- Interventions
- Alphanate
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- Up to 12 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Lexington, Kentucky • Minneapolis, Minnesota + 5 more
- Conditions
- Hemophilia A or B
- Interventions
- PF-06741086
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Chicago, Illinois
- Conditions
- Coagulation
- Interventions
- Not listed
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Protein C Deficiency
- Interventions
- Protein C Concentrate (Human)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Not listed
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Orange, California • Aurora, Colorado + 9 more
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- Uniplas, Cryosupernatant plasma
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Centreville, Virginia
- Conditions
- Hemophilia A
- Interventions
- Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 6 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Hemophilia A
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more
- Conditions
- Hemophilia A
- Interventions
- BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
- Conditions
- Hemophilia A
- Interventions
- ASC618
- Biological
- Lead sponsor
- ASC Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Hemophilia B
- Interventions
- AskBio009
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 11 more
- Conditions
- Hemophilia A, Prophylaxis of Bleeding
- Interventions
- Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- Autoimmune Thrombocytopenic Purpura
- Interventions
- Doxil
- Drug
- Lead sponsor
- Hematology and Oncology Specialists
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Metairie, Louisiana